Lonza Finance International NV, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a EUR 500 million Straight Bond. The Eurobond marks Lonza’s first drawdown under its newly established EMTN program. The bond has a maturity of 10 years and an annual coupon of 3.875%. The issuer is Lonza […]
continue readingQ1 2023 Qualitative Update: Business Performance In Line With Full-Year Trajectory
Robust commercial demand, with softer early-stage demand due to biotech funding constraints Growth project portfolio progressing in line with plan Outlook 2023 reiterated, with high single-digit CER sales growth and CORE EBITDA margin of 30 to 31% In its quarterly qualitative update, Lonza reported Q1 performance in line with the trajectory for 2023. In Biologics, […]
continue readingLonza Announces Results of the 2023 Annual General Meeting
Shareholders re-elected all existing members of the Board of Directors Albert M. Baehny was re-elected as Chairman of the Board of Directors A dividend of CHF 3.50 per share will be paid out starting from 11 May 2023 Attending and represented shareholders collectively held a total of 46,482,431 shares, representing 62.42% of the share capital […]
continue readingLonza Increases Straight Bond by CHF 150 Million
Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the increase of the Straight Bond issued on 8 February 2023 by CHF 150 million, in line with its financing plan for 2023. The increment has the same maturity (6.5 years) and coupon (2.100%) as the initial issuance. The […]
continue readingLonza Launches Share Buyback Program of up to CHF 2 Billion
On 3 April 2023, Lonza will launch a share buyback program of up to CHF 2 billion, as announced on 25 January 2023. Enabled by Lonza’s strong balance sheet and positive outlook, the share buyback program aims to return excess capital to shareholders without impacting the company’s capability to invest in organic growth and bolt-on […]
continue readingLonza Publishes Invitation to the 2023 Annual General Meeting and 2022 Annual and Sustainability Reports
Annual General Meeting to take place on 5 May 2023 at the Congress Center in Basel, Switzerland Albert M. Baehny proposed for re-election as Chairman of the Board of Directors, all current Board Members proposed for re-election KPMG proposed for re-election as auditors for the financial year 2023, with Deloitte Ltd, Zurich (CH) proposed […]
continue readingLonza Completes Expansion of Conjugation Facility in Visp (CH)
Expansion adds development and manufacturing capacity for pre-clinical, clinical and commercial supply of bioconjugates and antibody-drug conjugates The Visp (CH) investment includes two manufacturing suites and supporting infrastructure Additional manufacturing suites complement recent investments in Visp (CH) across small molecules and biologics development and manufacturing, including drug product Lonza, a preferred partner to the pharmaceutical, […]
continue readingLonza Prices CHF 300 Million Straight Bond with a 2.100% Coupon
Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a CHF 300 million straight-bond issue in line with its financing plan for 2023. The bond has a maturity of 6.5 years and an annual coupon of 2.100%. The issuer is Lonza Swiss Finance Ltd, Basel, […]
continue readingLonza Delivers Strong 2022 Performance with 15.1% CER Sales Growth and 32.1% CORE EBITDA Margin
In 2022, Lonza delivered CHF 6.2 billion sales and 15.1%1 CER sales growth CHF 2.0 billion CORE EBITDA resulted in a margin of 32.1% Growth investment continues as 2022 CAPEX reached 30% of sales Group Outlook 2023: high single-digit CER sales growth and CORE EBITDA margin of 30 to 31% Mid-Term Guidance 2024 confirmed Proposed dividend […]
continue reading